2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1092

Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE
Abstract Number: 356

Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Abstract Number: 2052

Immune Therapy of Rheumatoid Arthritis Patients with a Microbiome-Derived, Self/Non-Self Peptide Induces Clinically Relevant Immune Tolerance Pivoting on Immune Checkpoint-Expressing, Therapy-Induced Tregs
Abstract Number: 353

Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
Abstract Number: 363

Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
Abstract Number: 346

Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Abstract Number: 822

Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis
Abstract Number: 700

Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Abstract Number: 832

Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population
Abstract Number: 105

Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Abstract Number: 196

Immunology and Immunopharmacology at Point of Care: A Quality Improvement Teaching Initiative for Rheumatology Fellows
Abstract Number: 460

Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus
Abstract Number: 358

Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Abstract Number: 2042

Immunophenotypic Analysis of Tissue-Resident Memory T Cells in Rheumatoid Arthritis
Abstract Number: 1289

Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].